Key facts
- Synartro’s last known valuation is $5.1M (May 2023).
- It has raised $14.7M; the latest was Later Stage VC ($2.1M) in Oct 2025.
- Notable investors include Linc (Sweden), Phase2Phase Biopharma, Sciety.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Synartro
- ·The full record, as it builds
Funding rounds
No funding rounds for Synartro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synartro
Developer of drugs and a drug delivery platform designed to treat osteoarthritis in humans and animals. The company develops local injection treatments that provide superior and sustained efficacy without systemic side effects, which leads to improved treatments using patented delivery technology that offers a sustained drug release combined with existing proven drugs, enabling clinicians to slow down and stop the disease progression entirely.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2011
- Employees
- 6
- Website
- synartro.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Synartro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synartro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synartro in its N-PORT filings yet. We sweep new filings monthly.